A phase III, randomized, double-blind, placebo-controlled trial evaluating clinical outcomes following percutaneous coronary intervention in patients treated with an abciximab bolus plus 12-hour infusion given with either standard-dose weight-adjusted heparin or low-dose weight-adjusted heparin

Trial Profile

A phase III, randomized, double-blind, placebo-controlled trial evaluating clinical outcomes following percutaneous coronary intervention in patients treated with an abciximab bolus plus 12-hour infusion given with either standard-dose weight-adjusted heparin or low-dose weight-adjusted heparin

Completed
Phase of Trial: Phase III

Latest Information Update: 06 Apr 2007

At a glance

  • Drugs Abciximab; Heparin
  • Indications Coronary artery disease; Coronary stent thrombosis
  • Focus Therapeutic Use
  • Sponsors Janssen Biotech
  • Most Recent Events

    • 06 Apr 2007 Status changed from in progress to completed.
    • 16 Nov 2006 New trial record.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top